| 20-F |
Report
| Data |
20-F |
Mar 3, 2025 |
Dec 31, 2024 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Mar 3, 2025 |
Mar 3, 2025 |
| 6-K |
Report
|
US FDA ACCEPT 2 DEPEMOKIMAB INDICATION SUBMISSIONS |
Mar 3, 2025 |
Mar 3, 2025 |
| 6-K |
Report
|
ANCHOR RESULTS PRESENTED AT 2025 AAAAI |
Mar 3, 2025 |
Mar 3, 2025 |
| 6-K |
Report
|
TRANSACTION IN OWN SHARES |
Mar 3, 2025 |
Mar 3, 2025 |
| 6-K |
Report
|
TRANSACTION IN OWN SHARES |
Feb 28, 2025 |
Feb 28, 2025 |
| 6-K |
Report
|
TRANSACTION IN OWN SHARES |
Feb 27, 2025 |
Feb 27, 2025 |
| 6-K |
Report
|
GSK PUBLISHES ANNUAL REPORT 2024 |
Feb 27, 2025 |
Feb 27, 2025 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 26, 2025 |
Feb 26, 2025 |
| 6-K |
Report
|
TRANSACTION IN OWN SHARES |
Feb 26, 2025 |
Feb 26, 2025 |
| 6-K |
Report
|
TRANSACTION IN OWN SHARES |
Feb 25, 2025 |
Feb 25, 2025 |
| 6-K |
Report
|
GSK COMPLETES ACQUISITION OF IDRX, INC. |
Feb 24, 2025 |
Feb 24, 2025 |
| 6-K |
Report
|
GSK PLC COMMENCES SHARE BUYBACK PROGRAMME |
Feb 24, 2025 |
Feb 24, 2025 |
| 6-K |
Report
|
DIRECTORATE CHANGE |
Feb 21, 2025 |
Feb 21, 2025 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 21, 2025 |
Feb 21, 2025 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 21, 2025 |
Feb 21, 2025 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 21, 2025 |
Feb 21, 2025 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 21, 2025 |
Feb 21, 2025 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 21, 2025 |
Feb 21, 2025 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 21, 2025 |
Feb 21, 2025 |
| 6-K |
Report
|
NUCALA COPD SUBMISSION ACCEPTED IN CHINA |
Feb 20, 2025 |
Feb 20, 2025 |
| 6-K |
Report
|
GSK 5-IN-1 MENINGITIS VACCINE APPROVED BY US FDA |
Feb 18, 2025 |
Feb 18, 2025 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 13, 2025 |
Feb 13, 2025 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 11, 2025 |
Feb 11, 2025 |
| 6-K |
Report
|
FINAL RESULTS |
Feb 5, 2025 |
Feb 5, 2025 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Feb 3, 2025 |
Feb 3, 2025 |
| 6-K |
Report
|
DEPEMOKIMAB DUAL FILING IN CHINA AND JAPAN |
Jan 28, 2025 |
Jan 28, 2025 |
| 6-K |
Report
|
EMA ACCEPTS TWO SUBMISSIONS FOR DEPEMOKIMAB |
Jan 28, 2025 |
Jan 28, 2025 |
| 6-K |
Report
|
EMA ACCEPT REVIEW SHINGRIX SYRINGE PRESENTATION |
Jan 27, 2025 |
Jan 27, 2025 |
| 6-K |
Report
|
JEMPERLI EXPANDED APPROVAL IN THE EU |
Jan 21, 2025 |
Jan 21, 2025 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 16, 2025 |
Jan 16, 2025 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 15, 2025 |
Jan 15, 2025 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 14, 2025 |
Jan 14, 2025 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 13, 2025 |
Jan 13, 2025 |
| 6-K |
Report
|
GSK ENTERS AGREEMENT TO ACQUIRE IDRX, INC. |
Jan 13, 2025 |
Jan 13, 2025 |
| 6-K |
Report
|
SHINGRIX FULLY LIQUID ACCEPTED FOR US FDA REVIEW |
Jan 10, 2025 |
Jan 10, 2024 |
| 6-K |
Report
|
GSK ADC GETS FDA BREAKTHROUGH THERAPY DESIGNATION |
Jan 7, 2025 |
Jan 7, 2024 |
| 6-K |
Report
|
GSK'S NUCALA APPROVED IN CHINA FOR USE IN CRSWNP |
Jan 3, 2025 |
Jan 3, 2025 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jan 2, 2025 |
Jan 2, 2025 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 23, 2024 |
Dec 23, 2024 |
| 6-K |
Report
|
BLOCK LISTING APPLICATION |
Dec 20, 2024 |
Dec 20, 2024 |
| 6-K |
Report
|
HEADLINE RESULTS FROM PHASE III FIRST TRIAL |
Dec 20, 2024 |
Dec 20, 2024 |
| 6-K |
Report
|
JEMPERLI RECEIVES US FDA BREAKTHROUGH DESIGNATION |
Dec 16, 2024 |
Dec 16, 2024 |
| 6-K |
Report
|
EMA GRANTS PRIME DESIGNATION FOR GSK 227 |
Dec 16, 2024 |
Dec 16, 2024 |
| 6-K |
Report
|
JEMPERLI RECEIVES POSITIVE CHMP OPINION |
Dec 16, 2024 |
Dec 16, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 12, 2024 |
Dec 12, 2024 |
| 6-K |
Report
|
OVERALL SURVIVAL DATA PRESENTED FOR BLENREP |
Dec 9, 2024 |
Dec 9, 2024 |
| 6-K |
Report
|
BLENREP COMBINATION CHINA FILING ACCEPTANCE |
Dec 9, 2024 |
Dec 9, 2024 |
| 6-K |
Report
|
NUCALA COPD SUBMISSION ACCEPTED BY US FDA |
Dec 9, 2024 |
Dec 9, 2024 |
| 6-K |
Report
|
ZHIFEI CHINA COLLABORATION REVISED AND EXTENDED |
Dec 5, 2024 |
Dec 5, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 2, 2024 |
Dec 2, 2024 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Dec 2, 2024 |
Dec 2, 2024 |
| 6-K |
Report
|
GSK LIQUID MENINGITIS VACCINE AUTHORISED IN EU |
Nov 27, 2024 |
Nov 27, 2024 |
| 6-K |
Report
|
BLENREP COMBINATIONS ACCEPTED FOR US FDA REVIEW |
Nov 25, 2024 |
Nov 25, 2024 |
| 6-K |
Report
|
JAPAN APPROVES FIRST RSV VACCINE FOR ADULTS 50-59 |
Nov 22, 2024 |
Nov 22, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 19, 2024 |
Nov 19, 2024 |
| 6-K |
Report
|
GLISTEN TRIAL OF LINERIXIBAT MEETS ENDPOINT |
Nov 19, 2024 |
Nov 19, 2024 |
| SC 13D/A |
Report
|
AMENDMENT TO THE SCHEDULE 13D |
Nov 15, 2024 |
|
| 6-K |
Report
|
GSK ANNOUNCES OVERALL SURVIVAL RESULTS FOR BLENREP |
Nov 14, 2024 |
Nov 14, 2024 |
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
Nov 13, 2024 |
Nov 13, 2024 |
| SC 13G/A |
Report
|
AMENDMENT TO FORM SC 13G |
Nov 12, 2024 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 12, 2024 |
Nov 12, 2024 |
| 6-K |
Report
|
GSK PUBLISHES PROVISIONAL 2025 DIVIDEND DATES |
Nov 12, 2024 |
Nov 12, 2024 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Nov 1, 2024 |
Nov 1, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 30, 2024 |
Oct 30, 2024 |
| 6-K |
Report
|
3RD QUARTER RESULTS |
Oct 30, 2024 |
Oct 30, 2024 |
| 6-K |
Report
|
NEW POSITIVE AREXVY DATA IN YOUNGER ADULTS AT RISK |
Oct 24, 2024 |
Oct 24, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 17, 2024 |
Oct 17, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 16, 2024 |
Oct 16, 2024 |
| 6-K |
Report
|
FDA ACCEPTS NEW DRUG APPLICATION FOR GEPOTIDACIN |
Oct 16, 2024 |
Oct 16, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 15, 2024 |
Oct 15, 2024 |
| 6-K |
Report
|
POSITIVE RESULTS OF ANCHOR TRIALS OF DEPEMOKIMAB |
Oct 15, 2024 |
Oct 15, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 11, 2024 |
Oct 11, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 10, 2024 |
Oct 10, 2024 |
| 6-K |
Report
|
ZANTAC (RANITIDINE) LITIGATION SETTLEMENTS |
Oct 9, 2024 |
Oct 9, 2024 |
| 6-K |
Report
|
POSITIVE EFFICACY DATA OF AREXVY OVER 3 SEASONS |
Oct 8, 2024 |
Oct 8, 2024 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Oct 1, 2024 |
Oct 1, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 24, 2024 |
Sep 24, 2024 |
| 6-K |
Report
|
POSITIVE EU OPINION FOR GSK LIQUID MENVEO VACCINE |
Sep 24, 2024 |
Sep 24, 2024 |
| 6-K |
Report
|
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
Sep 18, 2024 |
Sep 18, 2024 |
| 6-K |
Report
|
JAPAN FILING ACCEPTANCE: BLENREP MULTIPLE MYELOMA |
Sep 17, 2024 |
Sep 17, 2024 |
| 6-K |
Report
|
CHINA BREAKTHROUGH THERAPY DESIGNATION FOR BLENREP |
Sep 13, 2024 |
Sep 13, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 12, 2024 |
Sep 12, 2024 |
| 6-K |
Report
|
POSITIVE MRNA FLU VACCINE PHASE II HEADLINE DATA |
Sep 12, 2024 |
Sep 12, 2024 |
| 6-K |
Report
|
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
Sep 11, 2024 |
Sep 11, 2024 |
| 6-K |
Report
|
CHANGE OF REGISTERED OFFICE |
Sep 11, 2024 |
Sep 11, 2024 |
| 6-K |
Report
|
UPDATE ON PHASE I/II THERAPEUTIC HSV VACCINE TRIAL |
Sep 11, 2024 |
Sep 11, 2024 |
| 6-K |
Report
|
DEPEMOKIMAB LATE-BREAKING DATA PRESENTED AT ERS |
Sep 9, 2024 |
Sep 9, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 6, 2024 |
Sep 6, 2024 |
| 6-K |
Report
|
POSITIVE PHASE III RESULTS FOR NUCALA IN COPD |
Sep 6, 2024 |
Sep 6, 2024 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Sep 3, 2024 |
Sep 3, 2024 |
| 6-K |
Report
|
EMA APPROVAL ON AREXVY FOR 50-59 AT RISK |
Aug 29, 2024 |
Aug 29, 2024 |
| 6-K |
Report
|
NUCALA APPROVED IN JAPAN FOR USE IN CRSWNP |
Aug 28, 2024 |
Aug 28, 2024 |
| 6-K |
Report
|
SENKU DESIGNATION FOR BEPIROVIRSEN IN JAPAN |
Aug 28, 2024 |
Aug 28, 2024 |
| 6-K |
Report
|
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
Aug 28, 2024 |
Aug 28, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Aug 21, 2024 |
Aug 21, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Aug 20, 2024 |
Aug 20, 2024 |
| 6-K |
Report
|
B7-H3 ADC US FDA BREAKTHROUGH THERAPY DESIGNATION |
Aug 20, 2024 |
Aug 20, 2024 |
| 6-K |
Report
|
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
Aug 16, 2024 |
Aug 16, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Aug 12, 2024 |
Aug 12, 2024 |
| 6-K |
Report
|
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
Aug 6, 2024 |
Aug 6, 2024 |
| 6-K |
Report
|
FDA EXPANDS JEMPERLI APPROVAL |
Aug 2, 2024 |
Aug 2, 2024 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Aug 1, 2024 |
Aug 1, 2024 |
| 6-K |
Report
|
2ND QUARTER RESULTS |
Jul 31, 2024 |
Jul 31, 2024 |
| 6-K |
Report
|
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
Jul 29, 2024 |
Jul 29, 2024 |
| 6-K |
Report
|
CHMP POSITIVE OPINION ON AREXVY FOR 50-59 AT RISK |
Jul 29, 2024 |
Jul 29, 2024 |
| 6-K |
Report
|
BLENREP EMA FILING ACCEPTANCE |
Jul 19, 2024 |
Jul 19, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 18, 2024 |
Jul 18, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 16, 2024 |
Jul 16, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 15, 2024 |
Jul 15, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 12, 2024 |
Jul 12, 2024 |
| 6-K |
Report
|
GSK AND CUREVAC COLLABORATION RESTRUCTURED |
Jul 3, 2024 |
Jul 3, 2024 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jul 1, 2024 |
Jul 1, 2024 |
| 6-K |
Report
|
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
Jun 28, 2024 |
Jun 28, 2024 |
| 6-K |
Report
|
EMA VALIDATES JEMPERLI MARKETING AUTHORISATION |
Jun 24, 2024 |
Jun 24, 2024 |
| 6-K |
Report
|
OMJJARA APPROVED IN JAPAN FOR MYELOFIBROSIS |
Jun 24, 2024 |
Jun 24, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jun 21, 2024 |
Jun 21, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jun 12, 2024 |
Jun 12, 2024 |
| 6-K |
Report
|
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
Jun 11, 2024 |
Jun 11, 2024 |
| 6-K |
Report
|
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
Jun 10, 2024 |
Jun 10, 2024 |
| 6-K |
Report
|
FDA APPROVES AREXVY FOR ADULTS 50-59 AT RISK |
Jun 10, 2024 |
Jun 10, 2024 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jun 3, 2024 |
Jun 3, 2024 |
| 6-K |
Report
|
UNPRECEDENTED RESULTS IN JEMPERLI TRIAL CONTINUE |
Jun 3, 2024 |
Jun 3, 2024 |
| 6-K |
Report
|
ASCO POSITIVE BLENREP DREAMM-8 TRIAL RESULTS |
Jun 3, 2024 |
Jun 3, 2024 |
| 6-K |
Report
|
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
Jun 3, 2024 |
Jun 3, 2024 |
| 6-K |
Report
|
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
May 24, 2024 |
May 24, 2024 |
| 6-K |
Report
|
POSITIVE PHASE III ASTHMA RESULTS FOR DEPEMOKIMAB |
May 21, 2024 |
May 21, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 20, 2024 |
May 20, 2024 |
| 6-K |
Report
|
CURRENT REPORT |
May 17, 2024 |
May 17, 2024 |
| 6-K |
Report
|
GSK COMPLETES SALE OF SHARES IN HALEON PLC |
May 17, 2024 |
May 17, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 14, 2024 |
May 14, 2024 |
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
May 13, 2024 |
May 13, 2024 |
| 6-K |
Report
|
RESULT OF AGM |
May 8, 2024 |
May 8, 2024 |
| 6-K |
Report
|
BOARD COMMITTEE CHANGE |
May 8, 2024 |
May 8, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 3, 2024 |
May 3, 2024 |
| 6-K |
Report
|
1ST QUARTER RESULTS |
May 1, 2024 |
May 1, 2024 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
May 1, 2024 |
May 1, 2024 |
| 6-K |
Report
|
US FDA ACCEPTS NEW INDICATION FILING FOR JEMPERLI |
Apr 24, 2024 |
Apr 24, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 19, 2024 |
Apr 19, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 17, 2024 |
Apr 17, 2024 |
| 6-K |
Report
|
RESULTS FROM LONG-TERM DATA RELATING TO SHINGRIX |
Apr 17, 2024 |
Apr 17, 2024 |
| 6-K |
Report
|
GSK ANNOUNCES ADDITIONAL EAGLE-1 RESULTS |
Apr 17, 2024 |
Apr 17, 2024 |
| 6-K |
Report
|
AMENDMENT - DIRECTOR/PDMR SHAREHOLDING |
Apr 16, 2024 |
Apr 16, 2024 |
| 6-K |
Report
|
FDA ACCEPTS GSK MENINGITIS VACCINE CANDIDATE FILE |
Apr 16, 2024 |
Apr 16, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 15, 2024 |
Apr 15, 2024 |
| 6-K/A |
Report
|
REPLACEMENT - TOTAL VOTING RIGHTS |
Apr 4, 2024 |
Apr 4, 2024 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Apr 2, 2024 |
Apr 2, 2024 |
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Mar 28, 2024 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 26, 2024 |
Mar 26, 2024 |
| 6-K |
Report
|
NOTICE OF AGM |
Mar 25, 2024 |
Mar 25, 2024 |
| 6-K |
Report
|
TRANSFER OF TREASURY SHARES |
Mar 22, 2024 |
Mar 22, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 22, 2024 |
Mar 22, 2024 |
| 6-K |
Report
|
NEW PHASE III JEMPERLI DATA IN ENDOMETRIAL CANCER |
Mar 18, 2024 |
Mar 18, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 13, 2024 |
Mar 13, 2024 |
| 6-K |
Report
|
BOARD COMMITTEE CHANGE |
Mar 8, 2024 |
Mar 8, 2024 |
| 6-K |
Report
|
GSK ANNOUNCES POSITIVE BLENREP DREAMM-8 RESULTS |
Mar 7, 2024 |
Mar 7, 2024 |
| 6-K |
Report
|
VIIV LAI VS ORAL SOC DATA IN ADHERENCE-CHALLENGED |
Mar 6, 2024 |
Mar 6, 2024 |
| 6-K |
Report
|
GSK ANNUAL REPORT 2023 ON FORM 20 F |
Mar 5, 2024 |
Mar 5, 2024 |
| 20-F |
Report
| Data |
20-F |
Mar 5, 2024 |
Dec 31, 2023 |
| 6-K |
Report
|
NEW VIIV LA FORMULATION POTENTIAL 4-MONTH DOSING |
Mar 5, 2024 |
Mar 5, 2024 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Mar 1, 2024 |
Mar 1, 2024 |
| 6-K |
Report
|
GSK PUBLISHES ANNUAL REPORT 2023 |
Mar 1, 2024 |
Mar 1, 2024 |
| 6-K |
Report
|
DIRECTORATE CHANGE |
Feb 29, 2024 |
Feb 29, 2024 |
| 6-K |
Report
|
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
Feb 29, 2024 |
Feb 29, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 26, 2024 |
Feb 26, 2024 |
| 6-K |
Report
|
GSK ANNOUNCES POSITIVE EAGLE-1 HEADLINE RESULTS |
Feb 26, 2024 |
Feb 26, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 22, 2024 |
Feb 22, 2024 |
| 6-K |
Report
|
VIIV LAI SUPERIOR TO ORALS IN ADHERENCE-CHALLENGED |
Feb 21, 2024 |
Feb 21, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 20, 2024 |
Feb 20, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 15, 2024 |
Feb 15, 2024 |
| 6-K |
Report
|
GSK COMPLETES ACQUISITION OF AIOLOS BIO |
Feb 15, 2024 |
Feb 15, 2024 |
| SC 13G/A |
Report
|
SC 13G/A |
Feb 13, 2024 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 13, 2024 |
Feb 13, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 13, 2024 |
Feb 13, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 13, 2024 |
Feb 13, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 12, 2024 |
Feb 12, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 12, 2024 |
Feb 12, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 12, 2024 |
Feb 12, 2024 |
| 6-K |
Report
|
US FDA FAST TRACK DESIGNATION FOR BEPIROVIRSEN |
Feb 12, 2024 |
Feb 12, 2024 |
| SC 13D/A |
Report
|
AMENDMENT TO SC 13D |
Feb 9, 2024 |
|
| SC 13G/A |
Report
|
AMENDMENT TO FORM SC 13G |
Feb 6, 2024 |
|
| SC 13G/A |
Report
|
AMENDMENT TO FORM SC 13G |
Feb 6, 2024 |
|
| 6-K |
Report
|
FDA ACCEPTS AREXVY FILING FOR ADULTS 50-59 AT RISK |
Feb 6, 2024 |
Feb 6, 2024 |
| 6-K |
Report
|
SHINGRIX 18+ AT RISK CHINA FILING REVIEW ACCEPTED |
Feb 6, 2024 |
Feb 6, 2024 |
| 6-K |
Report
|
GSK PRESENTS POSITIVE DREAMM-7 PHASE III DATA |
Feb 6, 2024 |
Feb 6, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 1, 2024 |
Feb 1, 2024 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Feb 1, 2024 |
Feb 1, 2024 |
| 6-K |
Report
|
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
Feb 1, 2024 |
Feb 1, 2024 |
| 6-K |
Report
|
FINAL RESULTS |
Jan 31, 2024 |
Jan 31, 2024 |
| 6-K |
Report
|
EMA ACCEPTS AREXVY FILING FOR ADULTS 50-59 AT RISK |
Jan 29, 2024 |
Jan 29, 2024 |
| 6-K |
Report
|
EUROPEAN COMMISSION AUTHORISES OMJJARA IN THE EU |
Jan 29, 2024 |
Jan 29, 2024 |
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Jan 19, 2024 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 19, 2024 |
Jan 19, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 17, 2024 |
Jan 17, 2024 |
| 6-K |
Report
|
CURRENT REPORT |
Jan 17, 2024 |
Jan 16, 2024 |
| 6-K |
Report
|
GSK COMPLETES SALE OF SHARES IN HALEON PLC |
Jan 17, 2024 |
Jan 17, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 16, 2024 |
Jan 16, 2024 |
| 6-K |
Report
|
NUCALA APPROVED IN CHINA FOR USE IN SEVERE ASTHMA |
Jan 10, 2024 |
Jan 10, 2024 |
| 6-K |
Report
|
GSK ENTERS AGREEMENT TO ACQUIRE AIOLOS BIO |
Jan 9, 2024 |
Jan 9, 2024 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jan 2, 2024 |
Jan 2, 2024 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 21, 2023 |
Dec 21, 2023 |
| 6-K |
Report
|
JEMPERLI PLUS ZEJULA TRIAL MEETS ENDPOINT |
Dec 18, 2023 |
Dec 18, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 13, 2023 |
Dec 13, 2023 |
| 6-K |
Report
|
JAPAN ACCEPTS AREXVY FILING FOR AT RISK ADULTS |
Dec 12, 2023 |
Dec 11, 2023 |
| 6-K |
Report
|
JEMPERLI PLUS CHEMOTHERAPY EU AUTHORISATION |
Dec 11, 2023 |
Dec 11, 2023 |
| 6-K |
Report
|
GSK PUBLISHES PROVISIONAL 2024 DIVIDEND DATES |
Dec 4, 2023 |
Dec 4, 2023 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Dec 1, 2023 |
Dec 1, 2023 |
| 6-K |
Report
|
BLOCK LISTING APPLICATION |
Nov 30, 2023 |
Nov 30, 2023 |
| 6-K |
Report
|
HOLDING(S) IN COMPANY |
Nov 29, 2023 |
Nov 29, 2023 |
| 6-K |
Report
|
GSK ANNOUNCES POSITIVE DREAMM-7 HEADLINE RESULTS |
Nov 27, 2023 |
Nov 27, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 21, 2023 |
Nov 21, 2023 |
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
Nov 15, 2023 |
Nov 15, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 13, 2023 |
Nov 13, 2023 |
| 6-K |
Report
|
GSK RECEIVES POSITIVE CHMP OPINION FOR MOMELOTINIB |
Nov 13, 2023 |
Nov 13, 2023 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Nov 1, 2023 |
Nov 1, 2023 |
| 6-K |
Report
|
3RD QUARTER RESULTS |
Nov 1, 2023 |
Nov 1, 2023 |
| 6-K |
Report
|
JEMPERLI TRIAL MEETS OVERALL SURVIVAL ENDPOINT |
Oct 30, 2023 |
Oct 30, 2023 |
| 6-K |
Report
|
NMPA APPROVES VOCABRIA+REKAMBYS IN CHINA |
Oct 26, 2023 |
Oct 26, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 25, 2023 |
Oct 25, 2023 |
| 6-K |
Report
|
NEW DATA FOR AREXVY, GSK'S RSV VACCINE |
Oct 25, 2023 |
Oct 25, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 20, 2023 |
Oct 20, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 18, 2023 |
Oct 18, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 17, 2023 |
Oct 17, 2023 |
| 6-K |
Report
|
JEMPERLI PLUS CHEMOTHERAPY POSITIVE CHMP OPINION |
Oct 16, 2023 |
Oct 16, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 13, 2023 |
Oct 13, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 12, 2023 |
Oct 12, 2023 |
| 6-K |
Report
|
ZANTAC (RANITIDINE) LITIGATION |
Oct 11, 2023 |
Oct 11, 2023 |
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Oct 10, 2023 |
|
| 6-K |
Report
|
GSK AND ZHIFEI ANNOUNCE VACCINE PARTNERSHIP |
Oct 10, 2023 |
Oct 10, 2023 |
| 6-K |
Report
|
CURRENT REPORT |
Oct 6, 2023 |
Oct 6, 2023 |
| 6-K |
Report
|
GSK COMPLETES SALE OF SHARES IN HALEON PLC |
Oct 6, 2023 |
Oct 6, 2023 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Oct 2, 2023 |
Oct 2, 2023 |
| 6-K |
Report
|
DIRECTORATE CHANGE |
Sep 27, 2023 |
Sep 27, 2023 |
| 6-K |
Report
|
GSK RSV VACCINE FOR OLDER ADULTS APPROVED IN JAPAN |
Sep 25, 2023 |
Sep 25, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 21, 2023 |
Aug 21, 2023 |
| 6-K |
Report
|
APRETUDE FOR PREP RECEIVES EMA APPROVAL |
Sep 19, 2023 |
Sep 19, 2023 |
| 6-K |
Report
|
FDA APPROVES OJJAARA (MOMELOTINIB) |
Sep 18, 2023 |
Sep 18, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 13, 2023 |
Sep 13, 2023 |
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Sep 11, 2023 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 11, 2023 |
Sep 11, 2023 |
| 6-K |
Report
|
MOMELOTINIB FILING ACCEPTED IN JAPAN |
Sep 11, 2023 |
Sep 11, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 6, 2023 |
Sep 6, 2023 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Sep 1, 2023 |
Sep 1, 2023 |
| 6-K |
Report
|
GSK'S NUCALA CRSWNP SUBMISSION ACCEPTED IN JAPAN |
Sep 1, 2023 |
Sep 1, 2023 |
| 6-K |
Report
|
HOLDING(S) IN COMPANY |
Aug 31, 2023 |
Aug 31, 2023 |
| 6-K |
Report
|
HOLDING(S) IN COMPANY |
Aug 31, 2023 |
Aug 31, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Aug 25, 2023 |
Aug 25, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Aug 23, 2023 |
Aug 23, 2023 |
| 6-K |
Report
|
SHINGRIX DATA DEMONSTRATE 100% EFFICACY IN CHINA |
Aug 23, 2023 |
Aug 23, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Aug 22, 2023 |
Aug 22, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Aug 10, 2023 |
Aug 10, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Aug 9, 2023 |
Aug 9, 2023 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Aug 1, 2023 |
Aug 1, 2023 |
| 6-K |
Report
|
FDA APPROVES NEW USE FOR JEMPERLI PLUS CHEMO |
Jul 31, 2023 |
Jul 31, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 31, 2023 |
Jul 31, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 28, 2023 |
Jul 28, 2023 |
| 6-K |
Report
|
2ND QUARTER RESULTS |
Jul 26, 2023 |
Jul 26, 2023 |
| 6-K |
Report
|
CABOTEGRAVIR LA FOR PREP RECEIVES POSITIVE CHMP |
Jul 24, 2023 |
Jul 24, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 20, 2023 |
Jul 20, 2023 |
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Jul 20, 2023 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 17, 2023 |
Jul 17, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 13, 2023 |
Jul 13, 2023 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jul 3, 2023 |
Jul 3, 2023 |
| 6-K |
Report
|
GSK COMPLETES ACQUISITION OF BELLUS HEALTH |
Jun 28, 2023 |
Jun 28, 2023 |
| 6-K |
Report
|
FDA FAST TRACK FOR GONORRHOEA VACCINE CANDIDATE |
Jun 27, 2023 |
Jun 27, 2023 |
| 6-K |
Report
|
GSK DAPRODUSTAT GAINS POSITIVE EMA CHMP OPINION |
Jun 26, 2023 |
Jun 26, 2023 |
| 6-K |
Report
|
SHINGRIX APPROVED IN JAPAN FOR ADULTS 18 AND OVER |
Jun 26, 2023 |
Jun 26, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jun 23, 2023 |
Jun 23, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jun 23, 2023 |
Jun 23, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jun 23, 2023 |
Jun 23, 2023 |
| 6-K |
Report
|
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
Jun 23, 2023 |
Jun 23, 2023 |
| 6-K |
Report
|
GSKS AREXVY RECOMMENDED BY ACIP |
Jun 22, 2023 |
Jun 22, 2023 |
| 6-K |
Report
|
SEASON TWO DATA FOR GSK AREXVY RSV OA VACCINE |
Jun 21, 2023 |
Jun 21, 2023 |
| 6-K |
Report
|
EXTENSION OF FDA REVIEW PERIOD FOR MOMELOTINIB |
Jun 16, 2023 |
Jun 16, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jun 12, 2023 |
Jun 12, 2023 |
| 6-K |
Report
|
EU AUTHORISATION OF GSKS RSV VACCINE AREXVY |
Jun 7, 2023 |
Jun 7, 2023 |
| 6-K |
Report
|
GSK RECEIVES US FDA FILE ACCEPTANCE FOR JEMPERLI |
Jun 6, 2023 |
Jun 6, 2023 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jun 1, 2023 |
Jun 1, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 22, 2023 |
May 22, 2023 |
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
May 16, 2023 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 15, 2023 |
May 15, 2023 |
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
May 15, 2023 |
May 15, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 12, 2023 |
May 12, 2023 |
| 6-K |
Report
|
MENABCWY VACCINE PRELIMINARY PHASE III RESULTS |
May 12, 2023 |
May 12, 2023 |
| 6-K |
Report
|
STATEMENT: ZANTAC LITIGATION UPDATE BC CANADA |
May 12, 2023 |
May 12, 2023 |
| 6-K |
Report
|
GSK COMPLETES SALE OF SHARES IN HALEON PLC |
May 12, 2023 |
May 12, 2023 |
| 6-K |
Report
|
CURRENT REPORT OF FOREIGN ISSUER |
May 12, 2023 |
May 11, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 9, 2023 |
May 9, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 4, 2023 |
May 4, 2023 |
| 6-K |
Report
|
RESULT OF AGM |
May 3, 2023 |
May 3, 2023 |
| 6-K |
Report
|
US FDA APPROVES GSKS RSV VACCINE FOR OLDER ADULTS |
May 3, 2023 |
May 3, 2023 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
May 2, 2023 |
May 2, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 28, 2023 |
Apr 28, 2023 |
| 6-K |
Report
|
GSK RSV OA VACCINE GAINS POSITIVE EMA CHMP OPINION |
Apr 27, 2023 |
Apr 27, 2023 |
| 6-K |
Report
|
1ST QUARTER RESULTS |
Apr 26, 2023 |
Apr 26, 2023 |
| 6-K |
Report
|
EMA VALIDATES JEMPERLI FILING FOR NEW INDICATION |
Apr 25, 2023 |
Apr 25, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 20, 2023 |
Apr 20, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 19, 2023 |
Apr 19, 2023 |
| 6-K |
Report
|
GSK REACHES AGREEMENT TO ACQUIRE BELLUS HEALTH INC |
Apr 18, 2023 |
Apr 18, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 17, 2023 |
Apr 17, 2023 |
| 6-K |
Report
|
GEPOTIDACIN POSITIVE PHASE III DATA |
Apr 17, 2023 |
Apr 17, 2023 |
| 20-F/A |
Report
| Data |
20-F/A |
Apr 17, 2023 |
Dec 31, 2022 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Apr 3, 2023 |
Apr 3, 2023 |
| 6-K |
Report
|
POSITIVE PHASE III RUBY RESULTS FOR JEMPERLI |
Mar 28, 2023 |
Mar 28, 2023 |
| 6-K |
Report
|
PUBLICATION OF 2023 AGM NOTICE |
Mar 27, 2023 |
Mar 27, 2023 |
| 6-K |
Report
|
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
Mar 24, 2023 |
Mar 24, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 21, 2023 |
Mar 21, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 20, 2023 |
Mar 20, 2023 |
| 6-K |
Report
|
POSITIVE PHASE III RESULTS FOR MENABCWY VACCINE |
Mar 14, 2023 |
Mar 14, 2023 |
| 6-K |
Report
|
NUCALA NDA ACCEPTED FOR REVIEW IN CHINA |
Mar 14, 2023 |
Mar 14, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 13, 2023 |
Mar 13, 2023 |
| 6-K |
Report
|
GSK ANNUAL REPORT 2022 ON FORM 20-F |
Mar 10, 2023 |
Mar 10, 2023 |
| 20-F |
Report
| Data |
20-F |
Mar 10, 2023 |
Dec 31, 2022 |
| 6-K |
Report
|
GSK PUBLISHES ANNUAL REPORT 2022 |
Mar 10, 2023 |
Mar 10, 2023 |
| 6-K |
Report
|
FDA AD COM VOTES TO SUPPORT GSK RSV OA VACCINE |
Mar 2, 2023 |
Mar 2, 2023 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Mar 1, 2023 |
Mar 1, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 27, 2023 |
Feb 27, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 23, 2023 |
Feb 23, 2023 |
| 6-K |
Report
|
VIIV HEALTHCARE ANNOUNCES CABENUVA POSITIVE DATA |
Feb 23, 2023 |
Feb 23, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 22, 2023 |
Feb 22, 2023 |
| 6-K |
Report
|
NEJM PUBLISHES GSK RSV OA VACCINE CANDIDATE TRIAL |
Feb 16, 2023 |
Feb 16, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 15, 2023 |
Feb 15, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 15, 2023 |
Feb 15, 2023 |
| SC 13G/A |
Report
|
SC 13G/A |
Feb 14, 2023 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 14, 2023 |
Feb 14, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 14, 2023 |
Feb 14, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 14, 2023 |
Feb 14, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 14, 2023 |
Feb 14, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 10, 2023 |
Feb 10, 2023 |
| 6-K |
Report
|
JEMPERLI FULL FDA APPROVAL FOLLOWING GARNET TRIAL |
Feb 10, 2023 |
Feb 10, 2023 |
| 6-K |
Report
|
JEMPERLI FDA ODAC POSITIVE OUTCOME |
Feb 10, 2023 |
Feb 10, 2023 |
| SC 13G |
Report
|
SCHEDULE 13G |
Feb 6, 2023 |
|
| 6-K |
Report
|
DAPRODUSTAT APPROVED BY US FDA FOR ANAEMIA OF CKD |
Feb 2, 2023 |
Feb 2, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 1, 2023 |
Feb 1, 2023 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Feb 1, 2023 |
Feb 1, 2023 |
| 6-K |
Report
|
BENLYSTA GRANTED ORPHAN DRUG DESIGNATION BY US FDA |
Feb 1, 2023 |
Feb 1, 2023 |
| 6-K |
Report
|
FINAL RESULTS |
Feb 1, 2023 |
Feb 1, 2023 |
| SC 13G |
Report
|
SCHEDULE 13G |
Jan 30, 2023 |
|
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Jan 20, 2023 |
|
| SC 13D/A |
Report
|
SCHEDULE 13D/A |
Jan 20, 2023 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 18, 2023 |
Jan 18, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 17, 2023 |
Jan 17, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 17, 2023 |
Jan 17, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 13, 2023 |
Jan 13, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 12, 2023 |
Jan 12, 2023 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jan 3, 2023 |
Jan 3, 2023 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 22, 2022 |
Dec 22, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 21, 2022 |
Dec 21, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 21, 2022 |
Dec 21, 2022 |
| 6-K |
Report
|
BOARD AND COMMITTEE CHANGES |
Dec 15, 2022 |
Dec 15, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 13, 2022 |
Dec 13, 2022 |
| 6-K |
Report
|
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
Dec 7, 2022 |
Dec 7, 2022 |
| 6-K |
Report
|
TRANSFER OF TREASURY SHARES |
Dec 5, 2022 |
Dec 5, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 2, 2022 |
Dec 2, 2022 |
| 6-K |
Report
|
JEMPERLI POSITIVE TRIAL IN ENDOMETRIAL CANCER |
Dec 2, 2022 |
Dec 2, 2022 |
| 6-K |
Report
|
EMA FILE ACCEPTED FOR MOMELOTINIB |
Dec 2, 2022 |
Dec 2, 2022 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Dec 1, 2022 |
Dec 1, 2022 |
| 6-K |
Report
|
GSK PUBLISHES PROVISIONAL 2023 DIVIDEND DATES |
Nov 25, 2022 |
Nov 25, 2022 |
| 6-K |
Report
|
BLENREP US UPDATE |
Nov 22, 2022 |
Nov 22, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 21, 2022 |
Nov 21, 2022 |
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
Nov 15, 2022 |
Nov 15, 2022 |
| SC 13D/A |
Report
|
SCHEDULE 13D/A |
Nov 14, 2022 |
|
| 6-K |
Report
|
GSK UPDATE: ZEJULA 2L IN US |
Nov 14, 2022 |
Nov 14, 2022 |
| 6-K |
Report
|
SANOFI-GSK COVID BOOSTER VACCINE APPROVED BY EU |
Nov 10, 2022 |
Nov 10, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 10, 2022 |
Nov 10, 2022 |
| 6-K |
Report
|
BLOCK LISTING APPLICATION |
Nov 10, 2022 |
Nov 10, 2022 |
| 6-K |
Report
|
DREAMM-3 PHASE III TRIAL FOR BLENREP |
Nov 7, 2022 |
Nov 7, 2022 |
| SC 13D |
Report
|
ACQUISITION OF BENEFICIAL OWNERSHIP |
Nov 4, 2022 |
|
| 6-K |
Report
|
IDMC RECOMMENDS GEPOTIDACIN EARLY EFFICACY STOP |
Nov 3, 2022 |
Nov 3, 2022 |
| 6-K |
Report
|
3RD QUARTER RESULTS |
Nov 2, 2022 |
Nov 2, 2022 |
| 6-K |
Report
|
GSK RSV VACCINE: US FDA PRIORITY REVIEW |
Nov 2, 2022 |
Nov 2, 2022 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Nov 1, 2022 |
Nov 1, 2022 |
| 6-K |
Report
|
EMA ACCEPTS GSK RSV OLDER ADULT VACCINE FOR REVIEW |
Oct 28, 2022 |
Oct 28, 2022 |
| 6-K |
Report
|
EMA VALIDATES MAA FOR CABOTEGRAVIR LA FOR PREP |
Oct 28, 2022 |
Oct 28, 2022 |
| 6-K |
Report
|
GSK ANNOUNCES FDA MEETING OUTCOME ON DAPRODUSTAT |
Oct 27, 2022 |
Oct 27, 2022 |
| 6-K |
Report
|
CONTRAST PHASE III PROGRAMME FOR OTILIMAB UPDATE |
Oct 27, 2022 |
Oct 27, 2022 |
| 6-K |
Report
|
BOARD COMMITTEE CHANGES |
Oct 25, 2022 |
Oct 25, 2022 |
| 6-K |
Report
|
RSV OLDER ADULT VACCINE SUBMISSION IN JAPAN |
Oct 21, 2022 |
Oct 21, 2022 |
| 6-K |
Report
|
MENVEO NEW SINGLE-VIAL APPROVED BY US FDA |
Oct 17, 2022 |
Oct 17, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 14, 2022 |
Oct 14, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 13, 2022 |
Oct 13, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 13, 2022 |
Oct 13, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 13, 2022 |
Oct 13, 2022 |
| 6-K |
Report
|
EFFICACY RESULTS FOR GSK'S OLDER ADULT RSV VACCINE |
Oct 13, 2022 |
Oct 13, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 12, 2022 |
Oct 12, 2022 |
| 6-K |
Report
|
US FDA APPROVES BOOSTRIX MATERNAL IMMUNISATION |
Oct 11, 2022 |
Oct 11, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 7, 2022 |
Oct 7, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 7, 2022 |
Oct 7, 2022 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Oct 3, 2022 |
Oct 3, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 30, 2022 |
Sep 30, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 26, 2022 |
Sep 26, 2022 |
| 6-K |
Report
|
GSK CHIEF FINANCIAL OFFICER SUCCESSION |
Sep 26, 2022 |
Sep 26, 2022 |
| 6-K |
Report
|
US FDA ODAC REVIEW OF ZEJULA PHASE III NOVA TRIAL |
Sep 22, 2022 |
Sep 22, 2022 |
| 6-K |
Report
|
GSK AND SPERO THERAPEUTICS LICENCE FOR TEBIPENEM |
Sep 22, 2022 |
Sep 22, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 21, 2022 |
Sep 21, 2022 |
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Sep 20, 2022 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 13, 2022 |
Sep 13, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 8, 2022 |
Sep 8, 2022 |
| 6-K |
Report
|
GSK PROVIDES UPDATE ON FDA REVIEW OF DAPRODUSTAT |
Sep 6, 2022 |
Sep 6, 2022 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Sep 1, 2022 |
Sep 1, 2022 |
| 6-K |
Report
|
GSK BOARD CHANGES |
Aug 24, 2022 |
Aug 24, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Aug 22, 2022 |
Aug 22, 2022 |
| 6-K |
Report
|
FDA NEW DRUG APPLICATION FILE ACCEPTANCE FOR MMB |
Aug 17, 2022 |
Aug 17, 2022 |
| 6-K |
Report
|
STATEMENT: ZANTAC (RANITIDINE) LITIGATION UPDATE |
Aug 17, 2022 |
Aug 17, 2022 |
| 6-K |
Report
|
GSK COMPLETES ACQUISITION OF AFFINIVAX, INC. |
Aug 16, 2022 |
Aug 16, 2022 |
| 6-K |
Report
|
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
Aug 12, 2022 |
Aug 12, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Aug 11, 2022 |
Aug 11, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Aug 10, 2022 |
Aug 10, 2022 |
| 6-K |
Report
|
CURRENT REPORT OF FOREIGN ISSUER |
Aug 3, 2022 |
Aug 3, 2022 |
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Aug 3, 2022 |
|
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Aug 1, 2022 |
Aug 1, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Aug 1, 2022 |
Aug 1, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 29, 2022 |
Jul 29, 2022 |
| 6-K |
Report
|
GSK BOARD CHANGE |
Jul 29, 2022 |
Jul 29, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 28, 2022 |
Jul 28, 2022 |
| SC 13D |
Report
|
SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP |
Jul 27, 2022 |
|
| 6-K |
Report
|
2ND QUARTER RESULTS |
Jul 27, 2022 |
Jul 27, 2022 |
| 6-K |
Report
|
HOLDING(S) IN COMPANY |
Jul 22, 2022 |
Jul 22, 2022 |
| 6-K |
Report
|
BOARD AND COMMITTEE CHANGES |
Jul 22, 2022 |
Jul 22, 2022 |
| 6-K |
Report
|
COMPLETION OF GSK SHARE CONSOLIDATION |
Jul 18, 2022 |
Jul 18, 2022 |
| 6-K |
Report
|
HALEON DEMERGER COMPLETION AND SHARE CONSOLIDATION |
Jul 18, 2022 |
Jul 18, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 12, 2022 |
Jul 12, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 8, 2022 |
Jul 8, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 8, 2022 |
Jul 8, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 8, 2022 |
Jul 8, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 8, 2022 |
Jul 8, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 8, 2022 |
Jul 8, 2022 |
| 6-K |
Report
|
RESULT OF GENERAL MEETING |
Jul 6, 2022 |
Jul 6, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 6, 2022 |
Jul 6, 2022 |
| 6-K |
Report
|
GSK DISCLOSE DISCONTINUED OPERATIONS FROM Q2 2022 |
Jul 5, 2022 |
Jul 5, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 5, 2022 |
Jul 5, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 5, 2022 |
Jul 5, 2022 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jul 1, 2022 |
Jul 1, 2022 |
| 6-K |
Report
|
GSK COMPLETES ACQUISITION OF SIERRA ONCOLOGY |
Jul 1, 2022 |
Jul 1, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jun 28, 2022 |
Jun 28, 2022 |
| 6-K |
Report
|
GSK FILES SHINGRIX 18+ AT RISK INDICATION IN JAPAN |
Jun 28, 2022 |
Jun 28, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jun 27, 2022 |
Jun 27, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jun 24, 2022 |
Jun 24, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jun 16, 2022 |
Jun 16, 2022 |
| 6-K |
Report
|
POSITIVE PHASE III DATA FOR GSK'S RSV OA VACCINE |
Jun 10, 2022 |
Jun 10, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jun 9, 2022 |
Jun 9, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jun 7, 2022 |
Jun 7, 2022 |
| 6-K |
Report
|
US FDA APPROVAL OF PRIORIX |
Jun 6, 2022 |
Jun 6, 2022 |
| 6-K |
Report
|
6-K |
Jun 1, 2022 |
Jun 1, 2022 |
| 6-K |
Report
|
DEMERGER UPDATE: PUBLICATION OF DOCUMENTS |
Jun 1, 2022 |
Jun 1, 2022 |
| 6-K |
Report
|
DEMERGER UPDATE: SUBMISSION OF DOCUMENTS TO FCA |
Jun 1, 2022 |
Jun 1, 2022 |
| 6-K |
Report
|
GSK TO ACQUIRE AFFINIVAX, INC. |
May 31, 2022 |
May 31, 2022 |
| 6-K |
Report
|
FURTHER APPOINTMENTS TO DESIGNATE HALEON BOARD |
May 31, 2022 |
May 31, 2022 |
| 6-K |
Report
|
GSK CERVARIX TWO-DOSE SCHEDULE APPROVED BY NMPA |
May 27, 2022 |
May 26, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 25, 2022 |
May 25, 2022 |
| 6-K |
Report
|
FORM 6-K |
May 23, 2022 |
May 23, 2022 |
| 6-K |
Report
|
IAIN MACKAY - EXTERNAL APPOINTMENT |
May 19, 2022 |
May 19, 2022 |
| 6-K |
Report
|
CHANGE OF NAME TO GSK PLC |
May 16, 2022 |
May 16, 2022 |
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
May 13, 2022 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 13, 2022 |
May 13, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 12, 2022 |
May 12, 2022 |
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
May 11, 2022 |
May 11, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 9, 2022 |
May 9, 2022 |
| 6-K |
Report
|
RESULT OF AGM |
May 4, 2022 |
May 4, 2022 |
| 6-K |
Report
|
DIRECTORATE CHANGE |
May 4, 2022 |
May 4, 2022 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
May 3, 2022 |
May 3, 2022 |
| 6-K |
Report
|
1ST QUARTER RESULTS |
Apr 27, 2022 |
Apr 27, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 26, 2022 |
Apr 26, 2022 |
| 6-K |
Report
|
DAPRODUSTAT APPLICATION ACCEPTED FOR REVIEW BY FDA |
Apr 19, 2022 |
Apr 19, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 14, 2022 |
Apr 14, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 14, 2022 |
Apr 14, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 14, 2022 |
Apr 14, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 13, 2022 |
Apr 13, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 13, 2022 |
Apr 13, 2022 |
| 6-K |
Report
|
GSK AGREES TO ACQUIRE SIERRA ONCOLOGY FOR $1.9BN |
Apr 13, 2022 |
Apr 13, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 12, 2022 |
Apr 12, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 12, 2022 |
Apr 12, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 12, 2022 |
Apr 12, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 12, 2022 |
Apr 12, 2022 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Apr 1, 2022 |
Apr 1, 2022 |
| 6-K |
Report
|
GSK - SEGMENT AND PRODUCT SALES REPORTING CHANGES |
Apr 1, 2022 |
Apr 1, 2022 |
| 6-K |
Report
|
PUBLICATION OF 2022 AGM NOTICE |
Mar 28, 2022 |
Mar 28, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 24, 2022 |
Mar 24, 2022 |
| 6-K |
Report
|
FDA UPDATE: CABENUVA ORAL LEAD-IN NOW OPTIONAL |
Mar 24, 2022 |
Mar 24, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 23, 2022 |
Mar 23, 2022 |
| 6-K |
Report
|
ISSUANCE OF NOTES |
Mar 23, 2022 |
Mar 23, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 16, 2022 |
Mar 16, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 15, 2022 |
Mar 15, 2022 |
| 6-K |
Report
|
APPOINTMENTS TO DESIGNATE HALEON BOARD |
Mar 15, 2022 |
Mar 15, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 11, 2022 |
Mar 11, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 9, 2022 |
Mar 9, 2022 |
| 6-K |
Report
|
GSK ANNUAL REPORT 2021 ON FORM 20-F |
Mar 8, 2022 |
Mar 8, 2022 |
| 20-F |
Report
| Data |
20-F |
Mar 8, 2022 |
Dec 31, 2021 |
| 6-K |
Report
|
GSK PUBLISHES ANNUAL REPORT 2021 |
Mar 4, 2022 |
Mar 4, 2022 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Mar 1, 2022 |
Mar 1, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 1, 2022 |
Mar 1, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 1, 2022 |
Mar 1, 2022 |
| 6-K |
Report
|
DAPRODUSTAT APPLICATION ACCEPTED FOR REVIEW BY EMA |
Mar 1, 2022 |
Mar 1, 2022 |
| 6-K |
Report
|
FOMR 6-K |
Feb 28, 2022 |
Feb 28, 2022 |
| 6-K |
Report
|
FORM 6-K |
Feb 28, 2022 |
Feb 28, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 24, 2022 |
Feb 24, 2022 |
| 6-K |
Report
|
CANADA APPROVAL FOR MEDICAGO GSK COVID-19 VACCINE |
Feb 24, 2022 |
Feb 24, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 23, 2022 |
Feb 23, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 22, 2022 |
Feb 22, 2022 |
| 6-K |
Report
|
GSK CONSUMER HEALTHCARE TO BE CALLED HALEON |
Feb 22, 2022 |
Feb 22, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 18, 2022 |
Feb 18, 2022 |
| 6-K |
Report
|
GSK GIVES UPDATE ON RSV MATERNAL VACCINE CANDIDATE |
Feb 18, 2022 |
Feb 18, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 17, 2022 |
Feb 17, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 17, 2022 |
Feb 17, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 17, 2022 |
Feb 17, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 17, 2022 |
Feb 17, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 17, 2022 |
Feb 17, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 16, 2022 |
Feb 16, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 14, 2022 |
Feb 14, 2022 |
| SC 13G |
Report
|
SC 13G |
Feb 14, 2022 |
|
| 6-K |
Report
|
TRANSFER OF TREASURY SHARES |
Feb 14, 2022 |
Feb 14, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 11, 2022 |
Feb 11, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 11, 2022 |
Feb 11, 2022 |
| SC 13G/A |
Report
|
AMENDMENT TO SC 13G |
Feb 10, 2022 |
|
| SC 13G |
Report
|
SCHEDULE 13G |
Feb 10, 2022 |
|
| SC 13G/A |
Report
|
AMENDMENT TO SC 13G |
Feb 10, 2022 |
|
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Feb 10, 2022 |
|
| SC 13G/A |
Report
|
AMENDMENT TO FORM SC 13G |
Feb 10, 2022 |
|
| 6-K |
Report
|
BENLYSTA APPROVED IN CHINA FOR LUPUS NEPHRITIS |
Feb 10, 2022 |
Feb 10, 2022 |
| 6-K |
Report
|
FINAL RESULTS |
Feb 9, 2022 |
Feb 9, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 9, 2022 |
Feb 9, 2022 |
| SC 13G/A |
Report
|
|
Feb 7, 2022 |
|
| 6-K |
Report
|
PUBLICATION OF FULL YEAR 2021 RESULTS |
Feb 7, 2022 |
Feb 7, 2022 |
| 6-K |
Report
|
GSK ANNOUNCES SETTLEMENT BETWEEN VIIV AND GILEAD |
Feb 2, 2022 |
Feb 2, 2022 |
| 6-K |
Report
|
FDA APPROVES VIIV HEALTHCARE'S SNDA FOR CABENUVA |
Feb 1, 2022 |
Feb 1, 2022 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Feb 1, 2022 |
Feb 1, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 26, 2022 |
Jan 26, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 20, 2022 |
Jan 20, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 19, 2022 |
Jan 19, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 19, 2022 |
Jan 19, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 19, 2022 |
Jan 19, 2022 |
| 6-K |
Report
|
TONY WOOD APPOINTED CSO DESIGNATE, GSK |
Jan 19, 2022 |
Jan 19, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 18, 2022 |
Jan 18, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 18, 2022 |
Jan 18, 2022 |
| 6-K |
Report
|
UPDATE - GSK CONSUMER HEALTHCARE |
Jan 18, 2022 |
Jan 18, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 14, 2022 |
Jan 14, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 13, 2022 |
Jan 13, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 11, 2022 |
Jan 11, 2022 |
| 6-K |
Report
|
US GOVT BUYS ADDITIONAL 600,000 SOTROVIMAB DOSES |
Jan 11, 2022 |
Jan 11, 2022 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jan 4, 2022 |
Jan 4, 2022 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 23, 2021 |
Dec 23, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 22, 2021 |
Dec 22, 2021 |
| 6-K |
Report
|
VIIV HEALTHCARE ANNOUNCES FDA APPROVAL OF APRETUDE |
Dec 21, 2021 |
Dec 21, 2021 |
| 6-K |
Report
|
CONSUMER HEALTHCARE CHAIR DESIGNATE APPOINTED |
Dec 20, 2021 |
Dec 20, 2021 |
| 6-K |
Report
|
XEVUDY APPROVED IN EUROPE TO TREAT COVID-19 |
Dec 17, 2021 |
Dec 17, 2021 |
| 6-K |
Report
|
GSK/SANOFI COVID-19 VACCINE BOOSTER & PH3 UPDATE |
Dec 15, 2021 |
Dec 15, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 13, 2021 |
Dec 13, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 13, 2021 |
Dec 13, 2021 |
| 6-K |
Report
|
MEDICAGO/GSK COVID-19 VACCINE POSITIVE PH3 DATA |
Dec 7, 2021 |
Dec 7, 2021 |
| 6-K |
Report
|
SOTROVIMAB RETAINS ITS ACTIVITY VS OMICRON VARIANT |
Dec 7, 2021 |
Dec 7, 2021 |
| 6-K |
Report
|
SOTROVIMAB RETAINS ITS ACTIVITY VS OMICRON VARIANT |
Dec 2, 2021 |
Dec 2, 2021 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Dec 1, 2021 |
Dec 1, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 24, 2021 |
Nov 24, 2021 |
| 6-K |
Report
|
GSK PUBLISHES PROVISIONAL 2022 DIVIDEND DATES |
Nov 24, 2021 |
Nov 24, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 23, 2021 |
Nov 23, 2021 |
| 6-K |
Report
|
NUCALA APPROVED IN EUROPE FOR MORE INDICATIONS |
Nov 17, 2021 |
Nov 17, 2021 |
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
Nov 15, 2021 |
Nov 15, 2021 |
| 6-K |
Report
|
PHASE III IM ADMINISTRATION DATA FOR SOTROVIMAB |
Nov 12, 2021 |
Nov 12, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 12, 2021 |
Nov 12, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 10, 2021 |
Nov 10, 2021 |
| 6-K |
Report
|
GSK SHARES POSITIVE PHASE III DATA FOR DAPRODUSTAT |
Nov 5, 2021 |
Nov 5, 2021 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Nov 1, 2021 |
Nov 1, 2021 |
| 6-K |
Report
|
3RD QUARTER RESULTS |
Oct 27, 2021 |
Oct 27, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 27, 2021 |
Oct 27, 2021 |
| 6-K |
Report
|
DIRECTORATE CHANGE |
Oct 27, 2021 |
Oct 27, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 15, 2021 |
Oct 15, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 14, 2021 |
Oct 14, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 14, 2021 |
Oct 14, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 13, 2021 |
Oct 13, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 12, 2021 |
Oct 12, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 12, 2021 |
Oct 12, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 12, 2021 |
Oct 12, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 12, 2021 |
Oct 12, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 12, 2021 |
Oct 12, 2021 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Oct 1, 2021 |
Oct 1, 2021 |
| SC 13G/A |
Report
|
AMENDMENT TO FORM SC 13G |
Sep 27, 2021 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 24, 2021 |
Sep 24, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 22, 2021 |
Sep 22, 2021 |
| 6-K |
Report
|
DIRECTOR DECLARATION |
Sep 20, 2021 |
Sep 20, 2021 |
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Sep 16, 2021 |
|
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Sep 16, 2021 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 13, 2021 |
Sep 13, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 9, 2021 |
Sep 9, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 7, 2021 |
Sep 7, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 3, 2021 |
Sep 3, 2021 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Sep 1, 2021 |
Sep 1, 2021 |
| 6-K |
Report
|
SK BIO & GSK START PH3 COVID-19 VACCINE TRIAL |
Aug 31, 2021 |
Aug 31, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Aug 25, 2021 |
Aug 25, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Aug 23, 2021 |
Aug 23, 2021 |
| 6-K/A |
Report
|
DIRECTOR/PDMR SHAREHOLDING - AMENDMENT |
Aug 13, 2021 |
Aug 13, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Aug 11, 2021 |
Aug 11, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Aug 11, 2021 |
Aug 11, 2021 |
| 6-K |
Report
|
BLOCK LISTING APPLICATION |
Aug 5, 2021 |
Aug 5, 2021 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Aug 2, 2021 |
Aug 2, 2021 |
| 6-K |
Report
|
2ND QUARTER RESULTS |
Jul 28, 2021 |
Jul 28, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 28, 2021 |
Jul 28, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 26, 2021 |
Jul 26, 2021 |
| 6-K |
Report
|
BOARD COMMITTEE CHANGES |
Jul 23, 2021 |
Jul 23, 2021 |
| 6-K |
Report
|
CEO DESIGNATE OF NEW CONSUMER HEALTHCARE COMPANY |
Jul 22, 2021 |
Jul 22, 2021 |
| 6-K |
Report
|
GSK ANNOUNCES DAPRODUSTAT PHASE 3 HEADLINE RESULTS |
Jul 16, 2021 |
Jul 16, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 16, 2021 |
Jul 16, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 15, 2021 |
Jul 15, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 14, 2021 |
Jul 14, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 14, 2021 |
Jul 14, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 13, 2021 |
Jul 13, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 13, 2021 |
Jul 13, 2021 |
| SC 13G |
Report
|
SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP |
Jul 12, 2021 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 12, 2021 |
Dec 7, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 12, 2021 |
Jul 12, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 9, 2021 |
Jul 9, 2021 |
| 6-K |
Report
|
GSK AND ALECTOR COLLABORATION IN IMMUNO-NEUROLOGY |
Jul 2, 2021 |
Jul 2, 2021 |
| 6-K |
Report
|
ELLIOTT ADVISORS (UK) LETTER TO GSK |
Jul 2, 2021 |
Jul 2, 2021 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jul 1, 2021 |
Jul 1, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jun 25, 2021 |
Jun 25, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jun 24, 2021 |
Jun 24, 2021 |
| 6-K |
Report
|
GSK TO DELIVER STEP-CHANGE IN GROWTH & PERFORMANCE |
Jun 23, 2021 |
Jun 23, 2021 |
| 6-K |
Report
|
VIIV/HALOZYME SIGN EXCLUSIVE LICENSING AGREEMENT |
Jun 22, 2021 |
Jun 22, 2021 |
| 6-K |
Report
|
GSK AND ITEOS ANNOUNCE COLLABORATION FOR EOS-448 |
Jun 14, 2021 |
Jun 14, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jun 11, 2021 |
Jun 11, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jun 9, 2021 |
Jun 9, 2021 |
| 6-K |
Report
|
TRC CAPITAL LETTER |
Jun 4, 2021 |
Jun 4, 2021 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jun 1, 2021 |
Jun 1, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 27, 2021 |
May 27, 2021 |
| 6-K |
Report
|
SANOFI AND GSK INITIATE NEW PHASE 3 CLINICAL STUDY |
May 27, 2021 |
May 27, 2021 |
| 6-K |
Report
|
GSK/VIR SOTROVIMAB FDA EMERGENCY USE AUTHORIZATION |
May 27, 2021 |
May 27, 2021 |
| SC 13D/A |
Report
|
AMENDED SCHEDULE 13D |
May 25, 2021 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 24, 2021 |
May 24, 2021 |
| 6-K |
Report
|
GSK/VIR SOTROVIMAB RECEIVES POSITIVE EMA OPINION |
May 21, 2021 |
May 21, 2021 |
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
May 18, 2021 |
May 18, 2021 |
| 6-K |
Report
|
MEDICAGO/GSK COVID-19 VACCINE POSITIVE PH2 RESULTS |
May 18, 2021 |
May 18, 2021 |
| 6-K |
Report
|
SANOFI/GSK COVID-19 VACCINE POSITIVE PH2 RESULTS |
May 17, 2021 |
May 17, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 13, 2021 |
May 13, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 11, 2021 |
May 11, 2021 |
| 6-K |
Report
|
EMTN PROSPECTUS |
May 11, 2021 |
May 11, 2021 |
| 6-K |
Report
|
BOARD AND COMMITTEE CHANGES |
May 6, 2021 |
May 6, 2021 |
| 6-K |
Report
|
RESULT OF AGM |
May 5, 2021 |
May 5, 2021 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
May 4, 2021 |
May 4, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 28, 2021 |
Apr 28, 2021 |
| 6-K |
Report
|
1ST QUARTER RESULTS |
Apr 28, 2021 |
Apr 28, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 26, 2021 |
Apr 26, 2021 |
| 6-K |
Report
|
EU APPROVES GSK'S JEMPERLI (DOSTARLIMAB-GXLY) |
Apr 23, 2021 |
Apr 23, 2021 |
| 6-K |
Report
|
FDA APPROVES GSK'S JEMPERLI (DOSTARLIMAB-GXLY) |
Apr 23, 2021 |
Apr 23, 2021 |
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Apr 16, 2021 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 16, 2021 |
Apr 16, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 15, 2021 |
Apr 15, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 15, 2021 |
Apr 15, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 14, 2021 |
Apr 14, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 14, 2021 |
Apr 14, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 12, 2021 |
Apr 12, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 12, 2021 |
Apr 12, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 9, 2021 |
Apr 9, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 9, 2021 |
Apr 9, 2021 |
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Apr 8, 2021 |
|
| 6-K |
Report
|
DIRECTORATE CHANGE |
Apr 6, 2021 |
Apr 6, 2021 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Apr 1, 2021 |
Apr 1, 2021 |
| 6-K |
Report
|
PUBLICATION OF 2021 AGM NOTICE |
Mar 30, 2021 |
Mar 30, 2021 |
| 6-K |
Report
|
GSK RESPIRATORY PRODUCT SALES REPORTING CHANGES |
Mar 30, 2021 |
Mar 30, 2021 |
| 6-K |
Report
|
MONCEF SLAOUI DEPARTS GALVANI BIOELECTRONICS |
Mar 24, 2021 |
Mar 24, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 23, 2021 |
Mar 23, 2021 |
| 6-K |
Report
|
CHAIR OF AUDIT & RISK COMMITTEE |
Mar 17, 2021 |
Mar 17, 2021 |
| 6-K |
Report
|
MEDICAGO AND GSK START PHASE 3 TRIAL |
Mar 16, 2021 |
Mar 16, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 15, 2021 |
Mar 15, 2021 |
| 6-K |
Report
|
ANNUAL REPORT 2020 ON FORM 20-F |
Mar 15, 2021 |
Mar 15, 2021 |
| 20-F |
Report
| Data |
20-F |
Mar 12, 2021 |
Dec 31, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 11, 2021 |
Mar 11, 2021 |
| 6-K |
Report
|
GSK AND VIR SHARE POSITIVE VIR-7831 DATA IN COVID |
Mar 11, 2021 |
Mar 11, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 10, 2021 |
Mar 10, 2021 |
| 6-K |
Report
|
ANNUAL FINANCIAL REPORT |
Mar 9, 2021 |
Mar 9, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 2, 2021 |
Mar 2, 2021 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Mar 1, 2021 |
Mar 1, 2021 |
| 6-K |
Report
|
GSK ANNOUNCES OTILIMAB DATA FOR TREATMENT OF COVID |
Feb 25, 2021 |
Feb 25, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 24, 2021 |
Feb 24, 2021 |
| 6-K |
Report
|
HOLDING(S) IN COMPANY |
Feb 24, 2021 |
Feb 24, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 23, 2021 |
Feb 23, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 22, 2021 |
Feb 22, 2021 |
| 6-K |
Report
|
SANOFI AND GSK INITIATE NEW PHASE 2 STUDY |
Feb 22, 2021 |
Feb 22, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 19, 2021 |
Feb 19, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 19, 2021 |
Feb 19, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 19, 2021 |
Feb 19, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 18, 2021 |
Feb 18, 2021 |
| 6-K |
Report
|
GSK/VIR COLLABORATE ON ANTIBODIES FOR INFLUENZA |
Feb 17, 2021 |
Feb 17, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 17, 2021 |
Feb 17, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 16, 2021 |
Feb 16, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 16, 2021 |
Feb 16, 2021 |
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Feb 12, 2021 |
|
| SC 13G/A |
Report
|
AMENDMENT TO FORM SC 13G |
Feb 12, 2021 |
|
| SC 13G/A |
Report
|
AMENDMENT TO FORM SC 13G |
Feb 12, 2021 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 12, 2021 |
Feb 12, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 12, 2021 |
Feb 12, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 12, 2021 |
Feb 12, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 10, 2021 |
Feb 10, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 10, 2021 |
Feb 10, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 4, 2021 |
Feb 4, 2021 |
| 6-K |
Report
|
FINAL RESULTS |
Feb 3, 2021 |
Feb 3, 2021 |
| 6-K |
Report
|
GSK/CUREVAC PARTNER ON NEW MRNA COVID-19 VACCINES |
Feb 3, 2021 |
Feb 3, 2021 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Feb 1, 2021 |
Feb 1, 2021 |
| SC 13G/A |
Report
|
|
Jan 29, 2021 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 26, 2021 |
Jan 26, 2021 |
| 6-K |
Report
|
FDA APPROVES VIIV HEALTHCARE'S CABENUVA FOR HIV |
Jan 22, 2021 |
Jan 22, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 20, 2021 |
Jan 20, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 20, 2021 |
Jan 20, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 20, 2021 |
Jan 20, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 19, 2021 |
Jan 19, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 19, 2021 |
Jan 19, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 15, 2021 |
Jan 15, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 15, 2021 |
Jan 15, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 13, 2021 |
Jan 13, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 11, 2021 |
Jan 11, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 11, 2021 |
Jan 11, 2021 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jan 4, 2021 |
Jan 4, 2021 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 30, 2020 |
Dec 30, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 23, 2020 |
Dec 23, 2020 |
| 6-K |
Report
|
VIIV FIRST LONG-ACTING HIV REGIMEN APPROVED IN EU |
Dec 21, 2020 |
Dec 21, 2020 |
| 6-K |
Report
|
SANOFI/ GSK UPDATE ON COVID VACCINE CANDIDATE |
Dec 11, 2020 |
Dec 11, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 10, 2020 |
Dec 10, 2020 |
| 6-K |
Report
|
BLOCK LISTING APPLICATION |
Dec 10, 2020 |
Dec 10, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 9, 2020 |
Dec 9, 2020 |
| SC 13D/A |
Report
|
AMENDMENT NO. 5 TO SC 13D |
Dec 7, 2020 |
|
| SC 13D/A |
Report
|
AMENDMENT NO. 2 TO SC 13D |
Dec 7, 2020 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 3, 2020 |
Dec 3, 2020 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Dec 1, 2020 |
Dec 1, 2020 |
| SC 13G |
Report
|
ACQUISITION OF BENEFICIAL OWNERSHIP |
Nov 30, 2020 |
|
| 6-K |
Report
|
GSK PUBLISHES PROVISIONAL 2021 DIVIDEND DATES |
Nov 27, 2020 |
Nov 27, 2020 |
| 6-K |
Report
|
EMTN SUPPLEMENTARY PROSPECTUS |
Nov 27, 2020 |
Nov 27, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 25, 2020 |
Nov 25, 2020 |
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
Nov 23, 2020 |
Nov 23, 2020 |
| 6-K |
Report
|
HOLDING(S) IN COMPANY |
Nov 19, 2020 |
Nov 19, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 17, 2020 |
Nov 17, 2020 |
| 6-K |
Report
|
MEDICAGO GSK PHASE 2/3 STUDY START |
Nov 12, 2020 |
Nov 12, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 12, 2020 |
Nov 12, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 12, 2020 |
Nov 12, 2020 |
| 6-K |
Report
|
VIIV'S CABOTEGRAVIR SUPERIOR FOR HIV PREVENTION |
Nov 9, 2020 |
Nov 9, 2020 |
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Nov 6, 2020 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 4, 2020 |
Nov 4, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 4, 2020 |
Nov 4, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 3, 2020 |
Nov 3, 2020 |
| 6-K |
Report
|
GSK SETS NEW ENVIRONMENTAL GOALS |
Nov 3, 2020 |
Nov 3, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 2, 2020 |
Nov 2, 2020 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Nov 2, 2020 |
Nov 2, 2020 |
| 6-K |
Report
|
HOLDING(S) IN COMPANY |
Oct 30, 2020 |
Oct 30, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 30, 2020 |
Oct 30, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 28, 2020 |
Oct 28, 2020 |
| 6-K |
Report
|
3RD QUARTER RESULTS |
Oct 28, 2020 |
Oct 28, 2020 |
| 6-K |
Report
|
SANOFI AND GSK SUPPORT COVAX - 200M VACCINE DOSES |
Oct 28, 2020 |
Oct 28, 2020 |
| 6-K |
Report
|
HOLDING(S) IN COMPANY |
Oct 22, 2020 |
Oct 22, 2020 |
| 6-K |
Report
|
POSITIVE CHMP OPINION VIIV LONG-ACTING HIV REGIMEN |
Oct 16, 2020 |
Oct 16, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 14, 2020 |
Oct 14, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 14, 2020 |
Oct 14, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 13, 2020 |
Oct 13, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 13, 2020 |
Oct 13, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 13, 2020 |
Oct 13, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 13, 2020 |
Oct 13, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 13, 2020 |
Oct 13, 2020 |
| 6-K |
Report
|
6-K |
Oct 1, 2020 |
Oct 1, 2020 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Oct 1, 2020 |
Oct 1, 2020 |
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Oct 1, 2020 |
|
| 6-K |
Report
|
6-K |
Sep 28, 2020 |
Sep 28, 2020 |
| 6-K |
Report
|
SANOFI/GSK AGREE UP TO 72M CANADA COVID DOSES |
Sep 22, 2020 |
Sep 22, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 11, 2020 |
Sep 11, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 10, 2020 |
Sep 10, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 9, 2020 |
Sep 9, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 9, 2020 |
Sep 9, 2020 |
| 6-K |
Report
|
SANOFI/GSK: PHASE 1/2 TRIAL OF COVID-19 VACCINE |
Sep 3, 2020 |
Sep 3, 2020 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Sep 1, 2020 |
Sep 1, 2020 |
| SC 13G |
Report
|
ACQUISITION OF BENEFICIAL OWNERSHIP |
Aug 24, 2020 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Aug 13, 2020 |
Aug 13, 2020 |
| 6-K |
Report
|
US FDA APPROVES GSKS BLENREP FOR MULTIPLE MYELOMA |
Aug 6, 2020 |
Aug 6, 2020 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Aug 3, 2020 |
Aug 3, 2020 |
| 6-K |
Report
|
SANOFI/GSK TO SUPPLY EU WITH 300M COVID 19 DOSES |
Aug 3, 2020 |
Aug 3, 2020 |
| SC 13D |
Report
|
ACQUISITION OF BENEFICIAL OWNERSHIP |
Aug 3, 2020 |
|
| 6-K |
Report
|
SANOFI & GSK PICKED FOR OP. WARP SPEED BY US GOV. |
Jul 31, 2020 |
Jul 31, 2020 |
| 6-K |
Report
|
2ND QUARTER RESULTS |
Jul 29, 2020 |
Jul 29, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 29, 2020 |
Jul 29, 2020 |
| 6-K |
Report
|
SANOFI AND GSK AGREE UK DOSES OF COVID 19 VACCINE |
Jul 29, 2020 |
Jul 29, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 28, 2020 |
Jul 28, 2020 |
| 6-K |
Report
|
GSK RECEIVES POSITIVE CHMP OPINION FOR BELAMAF |
Jul 24, 2020 |
Jul 24, 2020 |
| SC 13D |
Report
|
ACQUISITION OF BENEFICIAL OWNERSHIP |
Jul 22, 2020 |
|
| 6-K |
Report
|
GSK AND CUREVAC ENTER COLLABORATION |
Jul 20, 2020 |
Jul 20, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 15, 2020 |
Jul 15, 2020 |
| 6-K |
Report
|
FDA PANEL VOTES IN FAVOR OF BELANTAMAB MAFODOTIN |
Jul 15, 2020 |
Jul 15, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 14, 2020 |
Jul 14, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 13, 2020 |
Jul 13, 2020 |
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Jul 10, 2020 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 10, 2020 |
Jul 10, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 10, 2020 |
Jul 10, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 10, 2020 |
Jul 10, 2020 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jul 1, 2020 |
Jul 1, 2020 |
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Jun 29, 2020 |
|
| 6-K |
Report
|
GSK'S DAPRODUSTAT GAINS FIRST REGULATORY APPROVAL |
Jun 29, 2020 |
Jun 29, 2020 |
| SC 13D/A |
Report
|
AMENDED SC13D |
Jun 22, 2020 |
|
| 6-K |
Report
|
FDA ADVISORY COMMITTEE REVIEW BELANTAMAB MAFODOTIN |
Jun 19, 2020 |
Jun 19, 2020 |
| 6-K |
Report
|
6-K |
Jun 18, 2020 |
Jun 18, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jun 18, 2020 |
Jun 18, 2020 |
| 6-K |
Report
|
6-K |
Jun 17, 2020 |
Jun 17, 2020 |
| SC 13D/A |
Report
|
SC 13D/A |
Jun 17, 2020 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jun 16, 2020 |
Jun 16, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jun 11, 2020 |
Jun 11, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jun 9, 2020 |
Jun 9, 2020 |
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Jun 4, 2020 |
|
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jun 1, 2020 |
Jun 1, 2020 |
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
May 26, 2020 |
|
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
May 26, 2020 |
May 26, 2020 |
| 6-K |
Report
|
HOLDING(S) IN COMPANY |
May 19, 2020 |
May 19, 2020 |
| 6-K |
Report
|
VIIV PREP JAB SHOWS HIGH EFFICACY OVER DAILY PILL |
May 18, 2020 |
May 18, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 13, 2020 |
May 13, 2020 |
| 6-K |
Report
|
6-K |
May 12, 2020 |
May 12, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 11, 2020 |
May 11, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 7, 2020 |
May 7, 2020 |
| 6-K |
Report
|
RESULT OF AGM |
May 6, 2020 |
May 6, 2020 |
| SC 13G |
Report
|
ACQUISITION OF BENEFICIAL OWNERSHIP |
May 4, 2020 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
May 4, 2020 |
May 4, 2020 |
| 6-K |
Report
|
PUBLICATION OF A PROSPECTUS |
May 4, 2020 |
May 4, 2020 |
| 6-K |
Report
|
RIGHTS ATTACHED TO ORDINARY SHARES |
May 4, 2020 |
May 4, 2020 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
May 1, 2020 |
May 1, 2020 |
| 6-K |
Report
|
GSK'S ZEJULA APPROVED IN FIRST-LINE OVARIAN CANCER |
Apr 30, 2020 |
Apr 30, 2020 |
| 6-K |
Report
|
1ST QUARTER RESULTS |
Apr 29, 2020 |
Apr 29, 2020 |
| 6-K |
Report
|
ARRANGEMENTS FOR SHAREHOLDER WEBCAST |
Apr 29, 2020 |
Apr 29, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 16, 2020 |
Apr 16, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 16, 2020 |
Apr 16, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 16, 2020 |
Apr 16, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 14, 2020 |
Apr 14, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 14, 2020 |
Apr 14, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Apr 14, 2020 |
Apr 14, 2020 |
| 6-K |
Report
|
SANOFI AND GSK COLLABORATION TO FIGHT COVID-19 |
Apr 14, 2020 |
Apr 14, 2020 |
| 6-K |
Report
|
AGM - CHANGE OF ARRANGEMENTS |
Apr 9, 2020 |
Apr 9, 2020 |
| 6-K |
Report
|
GSK AND VIR BIOTECHNOLOGY ENTER COLLABORATION |
Apr 6, 2020 |
Apr 6, 2020 |
| 6-K |
Report
|
GSK COMPLETES DIVESTMENT OF HORLICKS |
Apr 1, 2020 |
Apr 1, 2020 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Apr 1, 2020 |
Apr 1, 2020 |
| 6-K |
Report
|
CONSUMER HEALTHCARE PRODUCT SALES CATEGORY CHANGES |
Mar 30, 2020 |
Mar 30, 2020 |
| 6-K |
Report
|
PUBLICATION OF AGM NOTICE |
Mar 24, 2020 |
Mar 24, 2020 |
| 6-K |
Report
|
DIRECTORATE CHANGE |
Mar 20, 2020 |
Mar 20, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 18, 2020 |
Mar 18, 2020 |
| 6-K |
Report
|
EMTN PROSPECTUS SUPPLEMENT UPDATE |
Mar 13, 2020 |
Mar 13, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 11, 2020 |
Mar 11, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Mar 9, 2020 |
Mar 9, 2020 |
| 6-K |
Report
|
PUBLICATION OF GSK 2019 FORM 20-F |
Mar 9, 2020 |
Mar 9, 2020 |
| 20-F |
Report
| Data |
20-F |
Mar 6, 2020 |
Dec 31, 2019 |
| 6-K |
Report
|
ANNUAL FINANCIAL REPORT |
Mar 4, 2020 |
Mar 4, 2020 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Mar 2, 2020 |
Mar 2, 2020 |
| SC 13G/A |
Report
|
AMENDMENT NO. 2 TO FORM SC 13G |
Feb 28, 2020 |
|
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Feb 27, 2020 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 21, 2020 |
Feb 21, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 20, 2020 |
Feb 20, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 20, 2020 |
Feb 20, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 20, 2020 |
Feb 20, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 19, 2020 |
Feb 19, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 19, 2020 |
Feb 19, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 19, 2020 |
Feb 19, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 19, 2020 |
Feb 19, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 19, 2020 |
Feb 19, 2020 |
| SC 13D/A |
Report
|
AMENDMENT NO. 4 TO SC 13D |
Feb 18, 2020 |
|
| SC 13D/A |
Report
|
AMENDMENT NO. 2 TO FORM SC 13D |
Feb 18, 2020 |
|
| SC 13G/A |
Report
|
AMENDMENT TO FORM SC 13G |
Feb 14, 2020 |
|
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Feb 14, 2020 |
|
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Feb 14, 2020 |
|
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Feb 14, 2020 |
|
| SC 13G/A |
Report
|
AMENDMENT TO FORM SC 13G |
Feb 14, 2020 |
|
| SC 13G |
Report
|
SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP |
Feb 14, 2020 |
|
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Feb 14, 2020 |
|
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Feb 14, 2020 |
|
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Feb 14, 2020 |
|
| SC 13G |
Report
|
SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP |
Feb 14, 2020 |
|
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Feb 14, 2020 |
|
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 12, 2020 |
Feb 12, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 11, 2020 |
Feb 11, 2020 |
| 6-K |
Report
|
TRANSFER OF TREASURY SHARES |
Feb 11, 2020 |
Feb 11, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 6, 2020 |
Feb 6, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Feb 5, 2020 |
Feb 5, 2020 |
| 6-K |
Report
|
FINAL RESULTS |
Feb 5, 2020 |
Feb 5, 2020 |
| SC 13G/A |
Report
|
|
Feb 5, 2020 |
|
| 6-K/A |
Report
|
GSK PUBLISHES PROVISIONAL 2020 DIVIDEND DATES |
Feb 3, 2020 |
Feb 3, 2020 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Feb 3, 2020 |
Feb 3, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 15, 2020 |
Jan 15, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 14, 2020 |
Jan 14, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 14, 2020 |
Jan 14, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 13, 2020 |
Jan 13, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 13, 2020 |
Jan 13, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 13, 2020 |
Jan 13, 2020 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jan 13, 2020 |
Jan 13, 2020 |
| 6-K |
Report
|
GSK ANNOUNCES ADDITION TO CORPORATE EXECUTIVE TEAM |
Jan 8, 2020 |
Jan 8, 2020 |
| 6-K |
Report
|
GSK PUBLISHES PROVISIONAL 2020 DIVIDEND DATES |
Jan 8, 2020 |
Jan 8, 2020 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Jan 2, 2020 |
Jan 2, 2020 |
| 6-K |
Report
|
VIIV HEALTHCARE RECEIVES COMPLETE RESPONSE LETTER |
Dec 23, 2019 |
Dec 23, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 18, 2019 |
Dec 18, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 18, 2019 |
Dec 18, 2019 |
| 6-K |
Report
|
BLOCKLISTING APPLICATION |
Dec 17, 2019 |
Dec 17, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 13, 2019 |
Dec 13, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 11, 2019 |
Dec 11, 2019 |
| 6-K |
Report
|
VIIV SUBMITS NDA TO FDA FOR FOSTEMSAVIR |
Dec 5, 2019 |
Dec 5, 2019 |
| 6-K |
Report
|
EMMA WALMSLEY - EXTERNAL APPOINTMENT |
Dec 4, 2019 |
Dec 4, 2019 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Dec 2, 2019 |
Dec 2, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Dec 2, 2019 |
Dec 2, 2019 |
| 6-K |
Report
|
BLOCK LISTING INTERIM REVIEW |
Nov 26, 2019 |
Nov 26, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 12, 2019 |
Nov 12, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 8, 2019 |
Nov 8, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 6, 2019 |
Nov 6, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 4, 2019 |
Nov 4, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Nov 1, 2019 |
Nov 1, 2019 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Nov 1, 2019 |
Nov 1, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 31, 2019 |
Oct 31, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 30, 2019 |
Oct 30, 2019 |
| 6-K |
Report
|
3RD QUARTER RESULTS |
Oct 30, 2019 |
Oct 30, 2019 |
| 6-K |
Report
|
GSK DIVESTS TWO TRAVEL VACCINES TO BAVARIAN NORDIC |
Oct 21, 2019 |
Oct 21, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 15, 2019 |
Oct 15, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 15, 2019 |
Oct 15, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 15, 2019 |
Oct 15, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 15, 2019 |
Oct 15, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 11, 2019 |
Oct 11, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 11, 2019 |
Oct 11, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 10, 2019 |
Oct 10, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Oct 1, 2019 |
Oct 1, 2019 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Oct 1, 2019 |
Oct 1, 2019 |
| 6-K |
Report
|
DATA SHOW ANTI-TUMOUR ACTIVITY WITH ICOS AGONIST |
Sep 30, 2019 |
Sep 30, 2019 |
| 6-K |
Report
|
PRIMA SHOWS ZEJULA IMPROVES PFS IN OVARIAN CANCER |
Sep 30, 2019 |
Sep 30, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 26, 2019 |
Sep 26, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 17, 2019 |
Sep 17, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 11, 2019 |
Sep 11, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 4, 2019 |
Sep 4, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 4, 2019 |
Sep 4, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Sep 4, 2019 |
Sep 4, 2019 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Sep 3, 2019 |
Sep 3, 2019 |
| 6-K |
Report
|
GSK - POSITIVE RESULTS FROM PIVOTAL DREAMM-2 STUDY |
Aug 23, 2019 |
Aug 23, 2019 |
| 6-K |
Report
|
VIIV RESULTS POSITIVE FOR EVERY 2 MONTH INJECTION |
Aug 22, 2019 |
Aug 22, 2019 |
| 6-K |
Report
|
GSK SUBMITS REGULATORY FILE IN JAPAN: DAPRODUSTAT |
Aug 21, 2019 |
Aug 21, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Aug 12, 2019 |
Aug 12, 2019 |
| 6-K |
Report
|
EU APPROVAL FOR NUCALA SELF-ADMINISTRATION |
Aug 1, 2019 |
Aug 1, 2019 |
| 6-K |
Report
|
TOTAL VOTING RIGHTS |
Aug 1, 2019 |
Aug 1, 2019 |
| 6-K |
Report
|
GSK COMPLETES TRANSACTION WITH PFIZER FOR NEW JV |
Aug 1, 2019 |
Aug 1, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 30, 2019 |
Jul 30, 2019 |
| 6-K |
Report
|
VIIV SUBMITS CABOTEGRAVIR TO EMA FOR HIV INJECTION |
Jul 29, 2019 |
Jul 29, 2019 |
| SC 13D/A |
Report
|
AMENDMENT TO FORM SC 13D |
Jul 25, 2019 |
|
| 6-K |
Report
|
2ND QUARTER RESULTS |
Jul 24, 2019 |
Jul 24, 2019 |
| 6-K |
Report
|
DIRECTOR/PDMR SHAREHOLDING |
Jul 24, 2019 |
Jul 24, 2019 |
| 6-K |
Report
|
VIIV 2DR TANGO SWITCH STUDY POSITIVE AT 48 WEEKS |
Jul 24, 2019 |
Jul 24, 2019 |
| 6-K |
Report
|
VIIV GEMINI STUDIES SHOW HIGH EFFICACY AT 96 WEEKS |
Jul 24, 2019 |
Jul 24, 2019 |
| 6-K |
Report
|
NON-EXECUTIVE CHAIRMAN |
Jul 24, 2019 |
Jul 24, 2019 |